TENX

Tenax Therapeutics, Inc. (TENX) | Rumor.io

Tenax Therapeutics

TENX

Attention (50-day avg)0.01%

Attention rank (50-day avg)#404

Bullish sentiment (50-day avg)60%

Price to earnings ratio2.41

Market capitalization69.2M

Earnings per share-1.48

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-52.6M

Social

What share of all stock conversation is about TENX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0.01% -0.03	0% +0

Sep 18

Insider buying at Tenax Therapeutics, Inc. (TENX) includes CEO Christopher Giordano, CFO Thomas Staab II, and Director Declan Doogan purchasing 10,850, 5,675, and 53,000 shares, respectively.
Insider buying at TENX is primarily with personal cash, not options or RSUs, and is seen as a vote of confidence in the company's prospects.
TENX insiders are buying despite recent price fluctuations, with one commentator expecting the stock to rise significantly after Phase 3 drug trials and FDA approvals.

Generated by AI

Sentiment

Of the messages about TENX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +12.24	83.56% +60.17	38.47% -45.94
Bearish	0% 0	0% -12.24	16.44% -60.17	61.53% +45.94

Bullish· Sep 9

Tenax Therapeutics, Inc. ($TENX) has shown potential for significant price appreciation, with one post predicting a 50-75% gain for the end of the month.
The company's CEO is seen as highly competent and capable, with one post stating that he "knows exactly where his company is going."
Historical data suggests that the stock has performed well after conferences, with one post noting that the stock went up 27% after the conference last year in September.

Bearish· Aug 31

The stock's price has been manipulated, with a significant drop from $2.58 to $1.80, and the author believes this is an attempt to keep prices low.
The company's market capitalization is $68 million, but it has over $100 million in cash, leading the author to believe that the institutions are selling to weak retail investors.
The stock's price has been heavily shorted, with the author suggesting that this is a plan to rob retail investors of their shares, and that the price will drop further to around $5.

Generated by AI

Topics

Of the messages about TENX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	57.14%	73.37%	21.59%
Technical Analysis	—	42.86%	11.49%	1.85%
Analysts	—	0%	14.88%	36.46%
Macro	—	0%	0%	39.42%
Controversies	—	0%	0.26%	0.06%
Earnings	—	0%	0%	0.62%

Earnings· Mar 15

$TENX is expected to report earnings in the morning.
There are no specific expectations mentioned for the earnings report.
The timing of the earnings report is AM, but the exact time is not specified.

Announcements· Feb 8

Tenax Therapeutics, Inc. (TENX) announced the pricing of a public offering of 1.6 million shares of its common stock and warrants to purchase up to 3.2 million shares of its common stock at a purchase price of $5.65 per share.
The public offering is expected to raise approximately $9 million in gross proceeds, which will be used to advance the initiation of sites and the enrollment and treatment of patients in its LEVEL trial, a Phase 3 trial of oral levosimendan.
Tenax Therapeutics has enrolled the first patient in its Phase 3 LEVEL study evaluating TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).

Technical Analysis· Aug 6

The stock has been trending upwards, with consistent higher highs and higher lows, and notable volume signaling increased buying interest.
A doji candle on the 15-minute chart may indicate a retracement, and the stock has topped at 5.30, which may be a hard resistance to break.
The stock has a low float and a catalyst, making it a potentially high-risk trade setup, but also a possible opportunity for a gap fill to 8 to $10.

Generated by AI

Community

Of the messages about TENX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	25%	18.75%	12.13%	21.95%
Newcomers	75%	81.25%	87.87%	78.05%

Regulars· Aug 25

The regulars are focused on the potential for a strategic alternative review to maximize shareholder value, possibly as a result of accumulating funds.
There is speculation that the upcoming drug presentation on August 28 could be a catalyst for the company.
The regulars are expecting a consolidation phase to strengthen the case for the stock, with some noting that every consolidation has resulted in increased strength.

Newcomers· Sep 17

The most bullish analyst price target for Tenax Therapeutics is $35.00 to $36.00, representing an implied upside of over 1,800% from its current trading price.
Tenax Therapeutics has requested a Type C meeting, which is seen as a positive development, and some users believe this could be a "lottery ticket".
Hedge funds and insiders are buying heavily into Tenax Therapeutics, which could potentially drive the price up to $35.00.

Generated by AI

News

Piper Sandler Remains a Buy on Tenax Therapeutics (TENX)

Detailed price information for Tenax Therapeutics (TENX-Q) from The Globe and Mail including charting and trades.

14d agotheglobeandmail.com

Tenax Therapeutics CFO buys $10,981 in common stock

14d agoInvesting.com

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

18d agoThe Globe and Mail

Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight

19d agoInvesting.com

Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics

21d agoInvesting.com

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics, Inc. (NASDAQ:TENX) has a possible route forward for TNX-103, but the Phase 3 LEVEL trial did not establish efficacy in the overall population. The study evaluated oral levosimendan in 241 patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. At Week 12, the adjusted improvement in six-minute walk […]

25d agoYahoo Finance

Also Discussed

Investors talking about TENX also mention

#	Name	Attention
1	Pulmatrix Inc.PULM	0%0
2	Vericel CorporationVCEL	0%0
3	Bio-Path Holdings Inc.BPTH	0%0
4	Arcadia Biosciences Inc.RKDA	0.01%0
5	BLPH - Bellerophon Therapeutics, Inc.	——
6	Xtant Medical Holdings Inc.XTNT	0%0
7	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
8	PBLA - Panbela Therapeutics, Inc.	——
9	Protalix BioTherapeutics, Inc.PLX	0%+0
10	Daré Bioscience, Inc.DARE	0%0

Tenax Therapeutics, Inc.

Healthcare
Biotechnology

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies. The company develops treatments for serious cardiovascular and pulmonary conditions, with a primary emphasis on pulmonary hypertension associated with heart failure with preserved ejection fraction. Its pipeline includes levosimendan-based programs, as well as other drug candidates aimed at improving outcomes in heart and lung disease. Tenax Therapeutics concentrates on advancing clinical-stage therapies for patients with high unmet medical needs, making it a specialized player in the pharmaceutical market. Headquartered in Chapel Hill, North Carolina, Tenax Therapeutics operates as a research-driven company centered on novel treatments for complex cardiopulmonary disorders.

Website

Location

101 Glen Lennox Drive

Chapel Hill, NC, 27517

United States

Social

What share of all stock conversation is about TENX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0.01% -0.03	0% +0

Sep 18

Insider buying at Tenax Therapeutics, Inc. (TENX) includes CEO Christopher Giordano, CFO Thomas Staab II, and Director Declan Doogan purchasing 10,850, 5,675, and 53,000 shares, respectively.
Insider buying at TENX is primarily with personal cash, not options or RSUs, and is seen as a vote of confidence in the company's prospects.
TENX insiders are buying despite recent price fluctuations, with one commentator expecting the stock to rise significantly after Phase 3 drug trials and FDA approvals.

Generated by AI

Sentiment

Of the messages about TENX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +12.24	83.56% +60.17	38.47% -45.94
Bearish	0% 0	0% -12.24	16.44% -60.17	61.53% +45.94

Bullish· Sep 9

Tenax Therapeutics, Inc. ($TENX) has shown potential for significant price appreciation, with one post predicting a 50-75% gain for the end of the month.
The company's CEO is seen as highly competent and capable, with one post stating that he "knows exactly where his company is going."
Historical data suggests that the stock has performed well after conferences, with one post noting that the stock went up 27% after the conference last year in September.

Bearish· Aug 31

The stock's price has been manipulated, with a significant drop from $2.58 to $1.80, and the author believes this is an attempt to keep prices low.
The company's market capitalization is $68 million, but it has over $100 million in cash, leading the author to believe that the institutions are selling to weak retail investors.
The stock's price has been heavily shorted, with the author suggesting that this is a plan to rob retail investors of their shares, and that the price will drop further to around $5.

Generated by AI

Topics

Of the messages about TENX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	57.14%	73.37%	21.59%
Technical Analysis	—	42.86%	11.49%	1.85%
Analysts	—	0%	14.88%	36.46%
Macro	—	0%	0%	39.42%
Controversies	—	0%	0.26%	0.06%
Earnings	—	0%	0%	0.62%

Earnings· Mar 15

$TENX is expected to report earnings in the morning.
There are no specific expectations mentioned for the earnings report.
The timing of the earnings report is AM, but the exact time is not specified.

Announcements· Feb 8

Tenax Therapeutics, Inc. (TENX) announced the pricing of a public offering of 1.6 million shares of its common stock and warrants to purchase up to 3.2 million shares of its common stock at a purchase price of $5.65 per share.
The public offering is expected to raise approximately $9 million in gross proceeds, which will be used to advance the initiation of sites and the enrollment and treatment of patients in its LEVEL trial, a Phase 3 trial of oral levosimendan.
Tenax Therapeutics has enrolled the first patient in its Phase 3 LEVEL study evaluating TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).

Technical Analysis· Aug 6

The stock has been trending upwards, with consistent higher highs and higher lows, and notable volume signaling increased buying interest.
A doji candle on the 15-minute chart may indicate a retracement, and the stock has topped at 5.30, which may be a hard resistance to break.
The stock has a low float and a catalyst, making it a potentially high-risk trade setup, but also a possible opportunity for a gap fill to 8 to $10.

Generated by AI

Community

Of the messages about TENX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	25%	18.75%	12.13%	21.95%
Newcomers	75%	81.25%	87.87%	78.05%

Regulars· Aug 25

The regulars are focused on the potential for a strategic alternative review to maximize shareholder value, possibly as a result of accumulating funds.
There is speculation that the upcoming drug presentation on August 28 could be a catalyst for the company.
The regulars are expecting a consolidation phase to strengthen the case for the stock, with some noting that every consolidation has resulted in increased strength.

Newcomers· Sep 17

The most bullish analyst price target for Tenax Therapeutics is $35.00 to $36.00, representing an implied upside of over 1,800% from its current trading price.
Tenax Therapeutics has requested a Type C meeting, which is seen as a positive development, and some users believe this could be a "lottery ticket".
Hedge funds and insiders are buying heavily into Tenax Therapeutics, which could potentially drive the price up to $35.00.

Generated by AI

Tenax Therapeutics

Social

Sep 18

Bullish· Sep 9

Bearish· Aug 31

Earnings· Mar 15

Announcements· Feb 8

Technical Analysis· Aug 6

Regulars· Aug 25

Newcomers· Sep 17

Piper Sandler Remains a Buy on Tenax Therapeutics (TENX)

Tenax Therapeutics CFO buys $10,981 in common stock

Wall Street Analysts Are Bullish on Top Healthcare Picks

Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight

Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Also Discussed

Tenax Therapeutics, Inc.

Company Information

Location

Piper Sandler Remains a Buy on Tenax Therapeutics (TENX)

Tenax Therapeutics CFO buys $10,981 in common stock

Wall Street Analysts Are Bullish on Top Healthcare Picks

Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight

Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Also Discussed

Social

Sep 18

Bullish· Sep 9

Bearish· Aug 31

Earnings· Mar 15

Announcements· Feb 8

Technical Analysis· Aug 6

Regulars· Aug 25

Newcomers· Sep 17